Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., Bauman, J. E., Bitting, R. L., Starodub, A., Jimeno, A., Reardon, D. A., Kaley, T., Iwamoto, F., Baehring, J. M., Subramaniam, D. S., … Keler, T. (2022). Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(8), e005147. https://doi.org/10.1136/jitc-2022-005147
Authors:
Rachel E. Sanborn
Michael J. Pishvaian
Margaret K. Callahan
Amy Weise
Branimir I. Šikić
Osama E. Rahma
Daniel C Cho
Naiyer A. Rizvi
Mario Sznol
Jose Lutzky
Julie E. Bauman
Rhonda L. Bitting
Alexander Starodub
Antonio Jimeno
David A. Reardon
Thomas Kaley
Fábio M. Iwamoto
Joachim M. Baehring
Deepa S. Subramaniam
Jeanny B. Aragon‐Ching
Thomas Hawthorne
Tracey Rawls
Michael Yellin
Tibor Keler
Affiliated Authors:
Naiyer A. Rizvi
Fábio M. Iwamoto
Author Keywords:
clinical trials as topic
combined modality therapy
immunotherapy
Publication Type:
Article
Unique ID:
10.1136/jitc-2022-005147
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: